Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
Progesterone intravaginal gel has been used to support embryo implantation
and to maintain pregnancies as part of an ART treatment regimen. Progestins are
secreted in breast milk.
Progesterone intravaginal gel should be stored at room temperature, 20 C to 25 C
(68 F to 77 F)
For ART, the recommended dose of the 8% gel is 90 mg once daily in women who
require progesterone supplementation,
and 90 mg twice daily in women with partial
or complete ovarian failure who require progesterone replacement. If
occurs, treatment may be continued until placental autonomy is achieved, up to
For the treatment of secondary amenorrhea, the 4% gel is administered
vaginally every other day for six doses. Women who do not respond should receive
the 8% gel.
DRUG CLASS AND MECHANISM:
Progesterone is a female hormone and is the principal progestational hormone.
Progestational hormones prepare the uterus (the womb) to receive and sustain the
fertilized egg. Progesterone promotes the development of the mammary glands,
causes changes in the
endometrium, which lines the uterus, relaxes uterine
smooth muscles, blocks
ovulation within the ovaries, and maintains pregnancy.
The FDA approved progesterone intravaginal gel in July 1997.